The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Ascending dose trials of a retroviral replicating vector (Toca 511) in patients with recurrent high-grade glioma.
Joan M. Robbins
Employment or Leadership Position - Tocagen
Stock Ownership - Tocagen
Tiffany T. Huang
Employment or Leadership Position - Tocagen
Stock Ownership - Tocagen
Douglas J. Jolly
Employment or Leadership Position - Tocagen
Stock Ownership - Tocagen
Noriyuki Kasahara
Consultant or Advisory Role - Tocagen
Stock Ownership - Tocagen
Research Funding - Tocagen
Manish K. Aghi
Research Funding - Tocagen
Michael A. Vogelbaum
Research Funding - Tocagen
Timothy F. Cloughesy
Consultant or Advisory Role - Tocagen
Research Funding - Tocagen
Susan Marina Chang
Research Funding - Tocagen
Santosh Kesari
Research Funding - Tocagen
Tom Mikkelsen
Research Funding - Tocagen
Steven N. Kalkanis
Research Funding - Tocagen
Joseph C. Landolfi
Research Funding - Tocagen
J. Bradley Elder
Research Funding - Tocagen
E. Antonio Chiocca
Research Funding - Tocagen
Harry E. Gruber
Employment or Leadership Position - Tocagen
Stock Ownership - Tocagen
Daniel Pertschuk
Employment or Leadership Position - Tocagen
Stock Ownership - Tocagen